scispace - formally typeset
J

John Q. Trojanowski

Researcher at University of Pennsylvania

Publications -  1538
Citations -  245534

John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology

TL;DR: Non-fluent/agrammatic primary progressive aphasia is a progressive neurodegenerative condition most prominently associated with slowed, effortful speech, and large-scale neural networks underlying effortful expression are assessed in patients with sporadic naPPA.
Journal ArticleDOI

Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites

TL;DR: Despite the abundance of A beta deposits in the cerebellar cortex of AD and older DS patients, neither PC bodies nor PC dendrites in physical contact with A beta lesions showed evidence of structural abnormalities.
Journal ArticleDOI

Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD.

Cyril Pottier, +119 more
TL;DR: A possible role for genes functioning within the TBK1-related immune pathway (e.g., DHX58, TRIM21, IRF7) in the genetic etiology of FTLD-TDP is discovered and strongly implicates the immune pathway in FTLD/TDP pathogenesis.
Journal ArticleDOI

Longitudinal decline in autopsy-defined frontotemporal lobar degeneration.

TL;DR: Moves consistently distinguishing between patient subgroups can be used to bolster diagnostic accuracy throughout the course of these diseases, while measures demonstrating undifferentiated longitudinal decline may serve as useful endpoints in treatment trials.